From a clinically relevant pain target to a possible analgesic treatment strategy
Abstract
Developing new analgesic treatments has been an extraordinary challenge, and unfortunately most attempts in the last three decades have failed. This is particularly true for the treatment of neuropathic pain, a debilitating disease characterized by abnormal chronic pain sensations that can develop after an injury to the somatosensory system. As a result, the therapeutic strategies available for neuropathic pain have not changed in at least 30 years, and consist mainly of gabapentinoids, anticonvulsants, antidepressants and morphine [1,2].
Read the paper
Related studies
- Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min
- De Novo Transcriptome Analysis and Detection of Antimicrobial Peptides of the American Cockroach Periplaneta americana (Linnaeus)
- Molecular Characterization and Expression Profiling of Tomato GRF Transcription Factor Family Genes in Response to Abiotic Stresses and Phytohormones
- Assembly of Tight Junction Strands: Claudin-10b and Claudin-3 Form Homo Tetrameric Building Blocks that Polymerise in a Channel-Independent Manner
- Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
- Machine Learning-Based SERS Chemical Space for Two-Way Prediction of Structures and Spectra of Untrained Molecules
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.